Previous 10 | Next 10 |
Financing provided exclusively by leading healthcare fund BVF Partners L.P. ZURICH, SWITZERLAND / ACCESSWIRE / December 7, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company, focused on the discovery and development o...
ZURICH, SWITZERLAND / ACCESSWIRE / December 7, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company, focused on the discovery and development of innovative therapies for patients with rare and complex central nervous...
More than 100,000 deaths in the U.S. alone each year due to overdose Global Opioid Use Disorder market projected to be approximately $5 Billion by 2028 Mazindol classified by the U.S. Drug Enforcement Agency (DEA) as a Schedule IV controlled substance versus currently available Schedule...
ZURICH, SWITZERLAND / ACCESSWIRE / November 23, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP), (NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central n...
NLS Pharma ( NASDAQ: NLSP ) has risen ~9% after the company said it had received a letter from the Nasdaq saying the panel had decided to grant its request to continue listing on the Nasdaq Stock Market. The continued listing is subject to the conditions that on or bef...
Swiss biopharma NLS Pharmaceutics ( NASDAQ: NLSP ) added ~8% on Monday after announcing that the Nasdaq approved the company’s request for continued listing subject to certain conditions. According to a letter sent by the Nasdaq, the continued listing depends on...
ZURICH, SWITZERLAND / ACCESSWIRE / November 14, 2022 / NLS Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous s...
Patients treated with Quilience® in the randomized Phase 2 trial continue to improve after rolling over into the open label extension (OLE) study Placebo patients in the randomized Phase 2 trial who received Quilience® in the OLE study achieved comparable results to treated p...
ODD for IH in the U.S. follows July 2022 grant of ODD for treatment of IH in Europe Currently only 1 drug approved in the United States to treat IH while no drugs are currently approved in Europe for IH High unmet medical need in this rare indication ZURICH, SWITZERLAND / ACCESSWIR...
Are you trying to play the penny stock game? Maybe you want to try your hand at higher-risk penny stocks . Many well-known companies have faced considerable selling pressure thanks to the stock market crash this year. That pressure has often taken plenty of “established” n...
News, Short Squeeze, Breakout and More Instantly...
NLS Pharmaceutics Ltd. Company Name:
NLSP Stock Symbol:
NASDAQ Market:
NLS Pharmaceutics Ltd. Website:
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 1.3% to $111.59 on volume of 240,827,673 shares Lipella Pharmaceuticals Inc. (LIPO) rose 122.5% to $0.8992 on volume of 193,926,302 shares PROSHARES TRUST (SQQQ) fell 0.5% to $9.05 on volume of 150,372,371...
The proposed transaction will create a Nasdaq-traded, biotechnology company with product candidates in advanced stages of clinical development and focused on advancing Kadimastem's allogeneic cell therapy platform Each of Kadimastem and NLS Pharmaceutics has received commitments of support f...
A look at the top 10 most actives in the United States Innovative Eyewear Inc. (LUCY) rose 78.0% to $0.58749 on volume of 130,454,575 shares Ocean Power Technologies Inc. (OPTT) rose 29.6% to $0.2073 on volume of 51,927,154 shares Cosmos Health Inc. (COSM) rose 64.9% to $1.12 on volume of...